<ul><li>Sun Pharma's Q4 review shows strong domestic growth offset by weakness in US generics.</li><li>Systematix maintains a 'Buy' rating and adjusts its estimates considering updated tax guidance and contributions from new launches in the specialty segment.</li><li>Sun Pharma plans a $100 million investment in new launches along with unveiling crucial clinical data on its new chemical entity pipeline, which includes Vibozilimod and Ilumya for psoriatic arthritis.</li><li>The clinical data release is expected to significantly influence sentiment regarding Sun Pharma's medium to long-term growth.</li></ul>

Sun Pharma Q4 Review: Strong Domestic Growth Offset By Weakness In US Generics; Systematix Maintains 'Buy'

Discover more